Information Provided By: 
Fly News Breaks for November 6, 2018
RIGL
Nov 6, 2018 | 20:42 EDT
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $8 price target on Rigel Pharmaceuticals after its Q3 results, citing its revenue beat. The analyst states that the management commentary has indicated a "limited payer pushback, physician satisfaction and breadth of prescribing" for Tavalisse, which suggests that its launch is off to a good start. Raymond maintains a positive outlook for Rigel Pharmaceuticals on Tavalisse opportunity as the launch progresses.
News For RIGL From the Last 2 Days
There are no results for your query RIGL
